Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

My initial reaction when unboxing my Arc’teryx Vertex Alpine GTX approach shoes was to reach for my best sunglasses, because the ‘Euphoria & Graphite’ color scheme of my test pair is bright enough to ...

Vertex Pharmaceuticals (VRTX) closed at $492.38 in the latest trading session, marking a -1.36% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.08%.

William Blair analyst Jake Roberge has maintained their bullish stance on VERX stock, giving a Buy rating today. Jake Roberge has given his Buy rating due to a combination of factors including ...

Vertex Pharmaceuticals stock: context for recent performance Vertex Pharmaceuticals (VRTX) has attracted attention recently ...

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...

JMP Securities analyst Patrick Walravens has maintained their bullish stance on VERX stock, giving a Buy rating today. Patrick Walravens has given his Buy rating due to a combination of factors that ...

Vertex Pharmaceuticals reported decent Q1 earnings, but the company missed estimates for both revenue and earnings. Vertex's diversification efforts are most visible in the progress of its pain ...